Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cost of Revenue: 2014-2016

Historic Cost of Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Dec 2016 value amounting to $692,000.

  • Viridian Therapeutics, Inc.\DE's Cost of Revenue rose 27.44% to $692,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $2.5 million, marking a year-over-year decrease of 8.25%. This contributed to the annual value of $2.5 million for FY2016, which is 0.43% down from last year.
  • According to the latest figures from Q4 2016, Viridian Therapeutics, Inc.\DE's Cost of Revenue is $692,000, which was up 15.53% from $599,000 recorded in Q3 2016.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Cost of Revenue ranged from a high of $954,000 in Q2 2014 and a low of $543,000 during Q4 2015.
  • Its 3-year average for Cost of Revenue is $724,250, with a median of $711,500 in 2014.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Cost of Revenue crashed by 30.47% in 2015, and later rose by 27.44% in 2016.
  • Viridian Therapeutics, Inc.\DE's Cost of Revenue (Quarterly) stood at $781,000 in 2014, then plummeted by 30.47% to $543,000 in 2015, then rose by 27.44% to $692,000 in 2016.
  • Its Cost of Revenue was $692,000 in Q4 2016, compared to $599,000 in Q3 2016 and $628,000 in Q2 2016.